Inhibikase Therapeutics
Inhibikase Therapeutics, a clinical-stage pharma company in Atlanta, develops kinase inhibitors for neurodegeneration treatment.
Founded
2010Inhibikase Therapeutics, a clinical-stage pharma company in Atlanta, develops kinase inhibitors for neurodegeneration treatment.
Inhibikase Therapeutics, founded in Atlanta, is a clinical-stage pharmaceutical company dedicated to developing and commercializing small-molecule kinase inhibitors for the treatment of neurodegenerative diseases, both within and outside the brain. The company's core mission is to provide safe and effective therapies for conditions like Parkinson's disease. Their flagship product, Risvodetinib, is currently undergoing clinical trials aimed at untreated Parkinson's patients, highlighting their focus on innovative solutions for neurodegeneration.
Notable figures affiliated with Inhibikase Therapeutics include leading researchers and industry experts in neurodegenerative disease treatment. The company has successfully completed enrollment for its Phase II trial of Risvodetinib and has expanded its therapeutic pipeline, reflecting significant progress in its R&D efforts. Additionally, Inhibikase has secured substantial funding through direct offerings, underscoring investor confidence in their mission. Overall, Inhibikase Therapeutics is making impactful strides in the field of neurodegenerative disease treatment, aiming to improve patient outcomes through advanced pharmaceutical innovations.
Companies similar to Inhibikase Therapeutics include KeifeRx, Kiniksa Pharmaceuticals, Eikonizo Therapeutics and Kinaset Therapeutics.
Inhibikase Therapeutics was founded in 2010.
Inhibikase Therapeutics' headquarters is located in Atlanta, GA, US.
Inhibikase Therapeutics' most recent funding round was for $10M (USD) in January 2023.
As of Jan 25, 2023, Inhibikase Therapeutics has raised a total of $11.2M (USD).
Inhibikase Therapeutics has 7 employees as of Feb 6, 2024.
Eikonizo Therapeutics
eikonizo.com
